Multicenter Study of the Safety and Effectiveness of Dermal Filler, Belotero®.

NCT00876265 | Completed Phase 3 Results

• 1 other identifier: MUS 90028-0622/1
• Study Type: interventional
• Target: 118
• Locations: 1 country
• Sites: 6

Brief Summary

This was a study to find out how an investigational product, Belotero, compares to a second product in people with facial wrinkles, such as nasolabial folds. Nasolabial folds are wrinkles on the face that go from the outside of the nostrils to the edges of the mouth. Additionally, this study determined Belotero is safe and tolerable and corrects facial wrinkles, such as nasolabial folds.

Conditions

Facial Wrinkles

Keywords

Facial wrinkles; Nasolabial fold

Outcome Measures

Primary Outcomes (1)

• Adjusted (LS) Mean Change From Baseline in Wrinkle Severity Rating Scale (SRS) Score of Each Nasolabial Fold (NLF) as Determined by the Blinded Evaluator at Week 12.

  The severity of the nasolabial folds was measured using the wrinkle Severity Rating Scale (SRS), where 0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, and 4 = Extreme, which is an ordinal scale.

  Baseline and Week 12 of follow-up

Study Arms (2)

Belotero

EXPERIMENTAL

Device: Belotero

Zyplast

ACTIVE COMPARATOR

Device: Zyplast

Interventions

Belotero DEVICE

Belotero, injectable hyaluronic acid gel device, implanted into the nasolabial fold in the Treatment Phase of the study (multiple injections of 0.1 to 0.2 mL, up to a maximum of 3 mL over 2 treatment sessions). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered.

Belotero

Zyplast DEVICE

Zyplast Collagen Implant, an injectable dermal collagen device, implanted into the nasolabial fold in the Treatment Phase of the study (average injection of 1.0 mL). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered. Zyplast was obtained by each site from commercially available supplies.

Zyplast

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects reviewed and signed a statement of Informed Consent and a HIPAA authorization prior to initiating any study-specific procedures. In addition, subjects were asked to provide a separate release for use of their photographs in publications. Subjects could refuse the photo release without jeopardizing their eligibility to participate in the study.
• Subjects were 18 - 75 years of age, and of any race or sex.
• Female subjects were postmenopausal for at least 1 year, had a hysterectomy, or had a tubal ligation; or, if of childbearing potential, agreed to use an approved method of birth control throughout the study (i.e., oral/systemic contraceptives, intrauterine device \[IUD\], or spermicide in combination with a barrier method of contraception), were abstinent, or were in a monogamous relationship with a vasectomized partner; and had a negative urine pregnancy test at the screening visit.
• Subjects had bilateral nasolabial folds with a severity score of 2 or 3 on the wrinkle SRS assessed by the blinded evaluator.
• Each subject had an adequate understanding of the language (spoken and written English or Spanish) and was willing to comply with the study requirements.

You may not qualify if:

• A personal history of allergic/anaphylactic reactions including hypersensitivity to local anesthetics (eg, lidocaine, etc), HA preparations, and/or gram-positive bacterial protein.
• A known history of keloids or bleeding disorders.
• An active inflammatory process in the nasolabial fold area (skin eruptions such as cysts, pimples, rashes, cancerous/pre-cancerous lesions, psoriasis, neurodermatitis, or any other active skin disease) or severe scarring that might interfere with study assessments.
• Women who were pregnant, planning to become pregnant during the study, or who were breast-feeding.
• Subjects who planned to undergo major facial surgery during the course of the study (eg, rhinoplasty \[with or without implant\], facelift, congenital defect repair, etc).
• Subjects with clinically important disease, as judged by the investigator, within 3 months of the study (eg, significant laboratory test abnormalities, myocardial infarct, stroke, cancer, connective tissue diseases \[scleroderma, systemic lupus erythematous\], systemic infection, uncontrolled diabetes, etc.), including those with medical conditions that might require the use of immunosuppressive medications during the trial (eg, severe, uncontrolled asthma, rheumatoid arthritis, autoimmune diseases, etc).
• Severe physical, neurological or mental disease.
• Excessive facial hair that might interfere with the evaluation of the wrinkle assessments.
• Any systemic or dermatologic disorder, which, in the opinion of the investigator,would interfere with the study results or increase the risk of adverse events (AEs).
• Participation in a clinical investigation within the 30 days prior to the first planned device administration or during this trial.

Sponsors & Collaborators

• Merz North America, Inc.: lead

Study Sites (6)

Total Skin and Beauty Dermatology Center

Birmingham, Alabama, 35205, United States

Location

Skin Care & Laser Physicians of Beverly Hills

Los Angeles, California, 90069, United States

Location

Maas Clinic

San Francisco, California, 94115, United States

Location

Savin Dermatology

New Haven, Connecticut, 06511, United States

Location

William Coleman, III, MD

Metairie, Louisiana, 70006, United States

Location

Dermatology Surgery and Laser Center

White Plains, New York, 10604, United States

Location

Results Point of Contact

• Title: Merz Aesthetics, Inc.
• Organization: Merz Aesthetics, Inc.

clinicaltrials@merzaesthetics.com

650-286-4000

Study Officials

• Rhoda Narins, MD

  Dermatology Surgery and Laser Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 3, 2009
• First Posted: April 6, 2009
• Study Start: December 1, 2006
• Primary Completion: July 1, 2007
• Study Completion: December 1, 2008
• Last Updated: April 26, 2013
• Results First Posted: January 19, 2012

Record last verified: 2013-04

Locations

US (6)